This is of particular importance as myotonia has emerged as a main clinical outcome for assessing the success of novel therapeutics in DM1, such as the phase III HARBOR trial investigating the effects of Delpacibart etedesiran—an antibody-oligonucleotide conjugate designed to knockdown DMPK expression (NCT06411288). This evidence concerns the gene DMPK and myotonic dystrophy type 1.